Skip to main content

Table 2 Baseline characteristics and demographics

From: A real world example of coverage with evidence development in Australia - ipilimumab for the treatment of metastatic melanoma

  Summary statistic Retrieval of 2 Year OS data
Age (years)
 Mean (sd) 63.3 (13.0)  
  < 40 years 53 (5.8%) 41 (77.4%)
 40–60 years 256 (28.1%) 211 (82.4%)
  > 60 years 601 (66.0%) 499 (83.0%)
Body weight (kg)
 Mean (sd) 80.9 (17.8)  
  < 70 kg 246 (27.0%) 199 (80.9%)
 70–90 kg 412 (45.3%) 349 (84.7%)
  > 90 kg 252 (27.7%) 203 (80.6%)
Gender
 Female 271 (29.9%) 221 (81.6%)
 Male 635 (70.1%) 528 (83.3%)
ECOG performance status
 Active 351 (38.7%) 293 (83.5%)
 Restricted 468 (51.7%) 65 (90.3%)
 Self-care capable 73 (8.1%) 379 (81.0%)
 Limited self-care capable 13 (1.4%) 11 (84.6%)
 Disabled 1 (0.1%) 1 (100%)
M Status
 M1a (distant skin, subcutaneous or nodal metastases) 74 (8.2%) 63 (85.2%)
 M1b (lung metastases) 156 (17.2%) 124 (79.5%)
 M1c (All other visceral metastases or any distant metastases with elevated serum LDH) 676 (74.6%) 562 (83.3%)
Previous brain metastases
 No 644 (71.1%) 517 (80.3%)
 Yes 262 (28.9%) 232 (88.9%)
Treatment naïve
 No 333 (36.7%) 278 (83.7%)
 Yes 573 (63.3%) 471 (82.2%)
Hospital
 Private 301 (35.6%) 242 (80.1%)
 Public 544 (64.4%) 456 (84.0%)
Community
 Rural 199 (23.5%) 169 (84.9%)
 Urban 647 (76.5%) 529 (81.9%)